Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419477 | 1.00 | KMT2A (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| SCHEMBL29356135 | 0.88 | CYP2D6 (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| SCHEMBL178013 | 0.88 | CYP2D6 (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Hydrochloric Acid SCHEMBL4456077 | 0.87 | CYP2D6 (0.98) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Hydrochloric Acid SCHEMBL29389905 | 0.87 | CYP2D6 (0.98) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Dihydrosanguinarine SCHEMBL16971032 | 0.86 | CYP2D6 (0.74) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Nitric Acid SCHEMBL3871762 | 0.82 | CYP2D6 (0.86) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Allocryptopine SCHEMBL29568468 | 0.82 | CYP2D6 (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Allocryptopine SCHEMBL673252 | 0.82 | CYP2D6 (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 | |
| Allocryptopine SCHEMBL30477770 | 0.82 | CYP2D6 (1.00) | KMT2ACYP2D6KDM4EMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240415129-A1 | BOTANICAL BASED BIO-INSECTICIDAL COMPOSITIONS FOR CONTROLLING PESTS AND IMPROVING THE PLANT PHYSIOLOGICAL PROCESS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2024-12-19 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | ELEONOR (BE) | 2023-06-08 | — | — | US | claimed |
| EP-4135666-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | Eleonor (BE) | 2023-02-22 | — | — | EP | claimed |
| CN-110715987-B | Quality control method for Yujiang corydalis amabilis | 张璐 | 2022-05-03 | — | — | CN | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-108938749-B | Pharmaceutical composition and preparation method and application thereof | 深圳市新鸿镁医疗器械有限公司 | 2021-11-12 | — | — | CN | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| WO-2010039218-A1 | METHOD OF PURIFYING CRUDE NOSCAPINE | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-20100081822-A1 | Method of purifying crude noscapine | MALLINCKRODT INC. (US) | 2010-04-01 | — | — | US | claimed |
| CN-100428956-C | Use of aza decyl meta pentalkenylone compounds | SAIDA BIOLOG TECHNOLOGY RES CT (CN) | 2008-10-29 | — | — | CN | claimed |
| CN-1748794-A | Use of aza decyl meta pentalkenylone compounds | SAIDA BIOLOG TECHNOLOGY RES CT (CN) | 2006-03-22 | — | — | CN | claimed |
| WO-2005012507-A1 | PRODUCTION OF PLANT SECONDARY METABOLITES USING ADSORPTION AND ELICITATION IN CELL SUSPENSION CULTURE | THE UNIVERSITY OF MELBOURNE (AU) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | KMT2A 4612/4885CYP2D6 324/4885KDM4E 4729/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | KMT2A 4612/4885CYP2D6 324/4885KDM4E 4729/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | KMT2A 3398/4885CYP2D6 94/4885KDM4E 3460/4885 |
| US-20230172916-A1 | COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERINE ALKALOID AND METHOD FOR MANUFACTURING SAME | MANBA, CROCC, MAN2A1 | KMT2A 4434/4885CYP2D6 2517/4885KDM4E 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.